TD Cowen Initiates Coverage On KalVista Pharma with Buy Rating, Announces Price Target of $30

Benzinga · 6d ago
TD Cowen analyst Stacy Ku initiates coverage on KalVista Pharma (NASDAQ:KALV) with a Buy rating and announces Price Target of $30.